What is neurodegeneration?
The Growing Global Burden of Neurodegenerative Disorders
Global neurological burden
In 2021, more than 3.4 billion people worldwide were living with a neurological condition, representing 43.1% of the global population. Neurological disorders are now the leading cause of disability and disease burden worldwide (443 million DALYs), with an 18.2% increase since 1990, largely driven by population ageing.
Future projections and scientific urgency
Without proactive intervention, the number of people affected by neurodegenerative diseases is projected to double by 2050. Current diagnostic delays severely limit opportunities for timely action, making innovative early-detection platforms essential.
Socio-economic impact and regional disparities
These conditions cause 11.1 million deaths annually and generate enormous costs in healthcare, lost productivity, and informal care. Low- and middle-income countries bear over 80% of deaths and DALYs, with wide variation in age-standardized incidence rates (from 7,295 in Ethiopia to 13,540 in Italy).
Our Scientific Focus
1.Mild Cognitive Impairment (MCI)
Definition and critical importance of early MCI detection
Mild Cognitive Impairment (MCI) represents a critical transitional stage between normal ageing and dementia, characterized by subtle cognitive decline that does not yet significantly impair daily functioning. Early detection relies on comprehensive neuropsychological evaluation, biomarker analysis, and advanced neuroimaging.
Risk stratification strategies in MCI
Risk stratification integrates genetic factors (e.g., APOE ε4 allele), lifestyle variables (physical activity, diet), and cardiovascular comorbidities. Advanced imaging techniques such as amyloid PET and structural MRI (hippocampal atrophy) significantly improve prognostic accuracy.
2.Alzheimer’s Disease Research
Core mechanisms: amyloid aggregation and tau pathology
Alzheimer’s disease pathogenesis is driven by the accumulation of amyloid-beta (Aβ) plaques and hyperphosphorylated tau forming neurofibrillary tangles, leading to synaptic loss and progressive cognitive decline
3.Digital Neurodiagnostics
AI-powered cognitive screening
AI-driven cognitive screening tools (virtual reality, serious games) deliver high accuracy and strong user engagement for detecting subtle cognitive changes that reflect real-world functioning.
4.Translational & Clinical Innovation
Rigorous biomarker validation
Translational validation of biomarkers requires robust clinical trials to confirm their diagnostic, prognostic, and therapeutic utility in central nervous system disorders.
Why Early Detection Matters
Critical intervention window and current late diagnosis
Early detection of neurodegenerative diseases is essential because current diagnoses typically occur after significant neuronal loss and symptom onset, severely limiting therapeutic opportunities.
Brain reserve and cognitive resilience
The brain reserve / cognitive reserve concept explains why higher reserve can delay symptom appearance despite underlying pathology, allowing lifestyle and therapeutic interventions to build neuronal resilience.
Emerging therapeutics and community-based screening
Disease-modifying treatments (anti-amyloid agents and beyond) show greatest efficacy in the pre-symptomatic phase, highlighting the urgent need for community and primary-care screening programs.
Neuroplasticity and lifestyle modification
Early intervention windows exploit neuroplasticity, enabling lasting changes in diet, physical exercise, and cognitive training that can slow disease progression.
From Scientific Discovery to Practical Solutions
Translating discoveries into laboratory tools
Advances in high-resolution imaging and gene editing are transforming fundamental discoveries (e.g., adult neurogenesis) into practical diagnostic and therapeutic tools.
Diagnostic reagents and biomarker-based solutions
Diagnostic reagents derived from basic research now enable biomarker-driven solutions for early and precise intervention.
Neuroscience research kits
Specialized research kits support the study of neural connectivity, bridging fundamental science to concrete clinical applications.
More Details
Personalized biomarker analysis platforms
AI- and genetics-powered biomarker analysis platforms are paving the way for individualized treatments, moving discoveries from the lab bench to the patient bedside.
More Details
Featured Insights
AI integration and Digital Neuro Fingerprints
Artificial intelligence accelerates biomarker discovery and fuses multimodal data into “Digital Neuro Fingerprints” for precise tracking of disease progression.
The Future of Digital Biomarkers in Alzheimer’s Detection
Use this snippet to build various types of components that feature a left- or right-aligned image alongside textual content. Duplicate the element to create a list that fits your needs.
Continue reading
AI integration and Digital Neuro Fingerprints
Artificial intelligence accelerates biomarker discovery and fuses multimodal data into “Digital Neuro Fingerprints” for precise tracking of disease progression.
Our Mission
To bridge neuroscience research, digital innovation and practical clinical solutions in order to improve early diagnosis and long-term brain health outcomes.
Neuro Research Tools & Solutions
We provide selected neuroscience-related research tools and laboratory products supporting neurodegenerative and cognitive research.